Immunobiology of renal transplantation

The Surgical Clinics of North America
J F Valente, J W Alexander

Abstract

The clinical application of our knowledge of the immune barriers to transplantation has advanced allo-organ replacement therapy to the level of routine practice, while simultaneously engendering a critical shortage in available donors. Recent work in xenotransplantation addresses this need. The current understanding of the immune barriers to transplantation has evolved to consider alternate responses to alloantigen, namely acceptance. The delineation and application of recent discoveries in T cell costimulatory events, antigen presentation, and differential T lymphocyte responses are opening pathways towards the development of tolerogenic protocols for use in clinical transplantation. This article presents a review of transplant immunobiology with special attention to antigen presentation and T-cell activation as phases of the immune response relevant to the discussion of transplant tolerance.

References

Jun 4, 1992·Nature·A L Goldberg, K L Rock
Mar 1, 1992·European Journal of Immunology·C Ardavin, K Shortman
Aug 21, 1992·Science·F Ramsdell, B J Fowlkes
Oct 24, 1991·The New England Journal of Medicine·E van TwuyverL P de Waal
Aug 2, 1990·Nature·T A Springer
Apr 1, 1991·Journal of Pediatric Surgery·S M WrenS T Ildstad
Jul 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·P W HedrickP Parham
Jun 30, 1989·Cell·R H Schwartz
Apr 24, 1987·Cell·J W KapplerP Marrack
Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·D A FrankM E Greenberg
Jun 1, 1995·Current Opinion in Immunology·L M Karnitz, R T Abraham
Jun 1, 1995·Current Opinion in Immunology·J JainA Rao
Jun 1, 1995·Current Opinion in Immunology·G M Griffiths
Jun 1, 1995·Current Opinion in Immunology·S L Reiner, R A Seder
Jun 1, 1995·Current Opinion in Immunology·J H Russell
Jun 1, 1995·Current Opinion in Immunology·T M Doherty
Sep 12, 1995·Proceedings of the National Academy of Sciences of the United States of America·K C NadeauN L Tilney
Jan 1, 1995·Annual Review of Medicine·D J Steele, H Auchincloss
Jan 1, 1995·Annual Review of Immunology·C L KaufmanS T Ildstad
May 1, 1995·Clinical Immunology and Immunopathology·A M Krensky, C Clayberger

❮ Previous
Next ❯

Citations

Sep 25, 2002·Transplantation Proceedings·A StephanA M Masri
Feb 19, 2002·Kidney International·Erwei SongUwe Heemann
Aug 24, 1999·Current Opinion in Nephrology and Hypertension·W W Hancock
Aug 29, 2007·International Journal of Nanomedicine·Li-Jiuan Shen, Fe-Lin Lin Wu
May 7, 2002·The Journal of Urology·Melinda K KnightJoseph W Segura
May 30, 2009·Clinical and Experimental Nephrology·Aamir Jalal Al Mosawi
Sep 3, 1999·Clinical and Diagnostic Laboratory Immunology·S A Kirkley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.